Slide 1: Q2 FY2025 Financial Results Overview
Q2 FY2025 FINANCIAL RESULTS OVERVIEW May 28, 2025
Slide 2: Safe Harbor
Thank You Safe Harbor for Your This presentation contains forward- looking statements (including, without successfully adapt its cost structures to continuing changes in business The company assumes no obligation to update the information in these Attention limitation, information, and future condit
Slide 3: Agilent Q2'25 Results
Agilent Q225 Results $ Q2 revenue growth exceeded the high end of our Revenue Operating Margin EPS guidance range in spite of the highly dynamic market environment during the quarter. On the bottom line, $1.67B 25.1% (2) $1.31 (2) +6.0% reported EPS was also above the high end of guidance, with +5.3
Slide 4: Q2 results by segment
$654M $713M $301M Life Sciences and Agilent CrossLab Group Applied Markets Group Diagnostics Markets Q2 results Group (LDG) (ACG) (AMG) by segment Growth +8% Reported Growth +7% Reported Growth -1% Reported +3% Core (1)(2) +9% Core (1)(2) 0% Core (1)(2) Operating Margin Operating Margin Operating Ma
Slide 5: Q2 revenue mix by geography
GEOGRAPHY PRODUCT TYPE SEGMENT Q2 revenue mix Americas 26% REVENUE (2) 33% (2) Europe 41% (2) 6% (1) REVENUE REVENUE GROWTH 2% (1) Asia Pacific 10% (1) GROWTH GROWTH (1) Core growth is reported growth adjusted for the effects of acquisitions and divestitures and FX; reconciliations to closest G AAP
Slide 6: Q2 revenue mix by product type
GEOGRAPHY PRODUCT TYPE SEGMENT % of total revenue Q2 revenue mix 67% Consumables Services Informatics Instruments 33% 06
Slide 7: Q2 revenue mix by segment
GEOGRAPHY PRODUCT TYPE SEGMENT % of total revenue Q2 revenue mix LDG 39% ACG 43% AMG 18% 07
Slide 8: Q2 revenue by end market
Q2 Core Share Growth(1) of Agilent Results Revenue (2) +6% 36% Strong performances in small molecule, CDMO, and Pharma ex-US biopharma more than offsets soft US biopharma Q2 REVENUE Academic & Growth across Asia helps mitigate impact of expected by Government pressure from federal gov’t policy in th
Slide 9: Transforming Agilent Innovation
Seahorse XF Flex Analyzer Infinity III 2x in sensitivity IGNITE LC Transforming 20% 8850 Smart GC with MS Agilent service connection rate increase Innovation 20%+ Up-to 5x throughput DELIVERING 1290 Infinity LC 45% energy savings H1 units ordered WORKFLOW EXCELLENCE AND 89% InfinityLab InfinityLab A
Slide 10: FY25 Revenue Guidance and Forward-looking Considerations
Net FY25 Revenue ($M) $6,730 $6,810 Guidance and Core Revenue +2.5% +3.5% Growth(2) Forward-looking -1.1% FX +2.0% to +2.2% M&A Considerations (1) EPS $5.54 $5.61 $15M Net Interest + Other Inc/(Exp) $1.5-1.6B Operating $282M Dividends FY25 FY25 Cash Flow FY25 Anti-dilutive $450M CapEx 285M Share sha
Slide 11: Q3 Guidance and Forward-looking Considerations
Net Q325 Revenue ($M) $1,645 $1,675 Guidance and Core Revenue +1.7% +3.6% Growth(2) Forward-looking +0.6% FX, +1.9% M&A Considerations (1) EPS $1.35 $1.37 Net Interest + Anti-dilutive $0M Other Inc/(Exp) 284M Share Count share repurchases Q3 Q3 at a minimum(3) (1) As of May 28, 2025, based on foreca
Slide 12: Get in touch with us
Get in touch with us Trusted Answers investor_relations@agilent.com www.investor.agilent.com